Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Basit Öğe Kaydı
dc.authoridEvrensel, Turkkan/0000-0002-9732-5340
dc.authoridGumusay, Ozge/0000-0002-6236-9829
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridSumbul, Ahmet T/0000-0002-5573-906X
dc.authoridÜrün, Yüksel/0000-0002-9152-9887
dc.authoridArtac, Mehmet/0000-0003-2335-3354
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authorwosidEvrensel, Turkkan/AAJ-1027-2021
dc.authorwosidGumusay, Ozge/AAT-3435-2021
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidhaksoyler, veysel/AAN-3762-2021
dc.authorwosidSumbul, Ahmet T/D-4793-2014
dc.authorwosidÜrün, Yüksel/AAQ-3612-2020
dc.authorwosidArtac, Mehmet/AAF-8158-2020
dc.contributor.authorEsin, Ece
dc.contributor.authorOksuzoglu, B.
dc.contributor.authorBilici, A.
dc.contributor.authorCicin, I.
dc.contributor.authorKostek, O.
dc.contributor.authorKaplan, M. A.
dc.contributor.authorAksoy, S.
dc.date.accessioned2024-06-12T11:12:18Z
dc.date.available2024-06-12T11:12:18Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.en_US
dc.identifier.doi10.1007/s00280-018-3712-7
dc.identifier.endpage143en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1en_US
dc.identifier.pmid30377778en_US
dc.identifier.scopus2-s2.0-85056003618en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage131en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-018-3712-7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23113
dc.identifier.volume83en_US
dc.identifier.wosWOS:000458407200014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectAntiher2en_US
dc.subjectVisceral Metastasisen_US
dc.subjectBrain Metastasisen_US
dc.subjectClinical-Outcomesen_US
dc.subjectOlder Patientsen_US
dc.subjectDocetaxelen_US
dc.subjectTrialen_US
dc.subjectSurvivalen_US
dc.subjectPlusen_US
dc.subjectChemotherapyen_US
dc.subjectPaclitaxelen_US
dc.subjectCleopatraen_US
dc.subjectTherapyen_US
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu